Researchers identify the mutations that drive resistance to PI3K inhibitors in breast cancer, find they can be overcome
by Mass General BrighamSecondary mutations in the PI3K/AKT pathway emerge during treatment with inavolisib and lead to acquired resistance. A-B, Droplet digital PCR analysis of serial ctDNA sampl
Updated on: June 24,2024
8
Researchers identify the mutations that drive resistance to PI3K inhibitors in breast cancer, find they can be overcome
by Mass General BrighamSecondary mutations in the PI3K/AKT pathway emerge during treatment with inavolisib and lead to acquired resistance. A-B, Droplet digital PCR analysis of serial ctDNA sampl
Updated on:June 24,2024
8